BR112018008401A2 - método para tratamento de uma condição, composição, e, uso de uma composição. - Google Patents

método para tratamento de uma condição, composição, e, uso de uma composição.

Info

Publication number
BR112018008401A2
BR112018008401A2 BR112018008401A BR112018008401A BR112018008401A2 BR 112018008401 A2 BR112018008401 A2 BR 112018008401A2 BR 112018008401 A BR112018008401 A BR 112018008401A BR 112018008401 A BR112018008401 A BR 112018008401A BR 112018008401 A2 BR112018008401 A2 BR 112018008401A2
Authority
BR
Brazil
Prior art keywords
composition
treating
condition
methods
glucan
Prior art date
Application number
BR112018008401A
Other languages
English (en)
Other versions
BR112018008401B1 (pt
Inventor
paul horst Geoffrey
bernard levine Robert
Original Assignee
Kemin Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Ind Inc filed Critical Kemin Ind Inc
Publication of BR112018008401A2 publication Critical patent/BR112018008401A2/pt
Publication of BR112018008401B1 publication Critical patent/BR112018008401B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

o presente pedido se refere ao beta-1,3-glucano e ao uso do mesmo para modular a imunidade no corpo humano. também são providos métodos para o tratamento e/ou prevenção de colesterol alto, dia¬betes e alergias. também são providos métodos para o tratamento e/ou prevenção da inflamação intestinal.
BR112018008401-8A 2015-10-28 2016-10-27 Uso de uma composição BR112018008401B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562247629P 2015-10-28 2015-10-28
US62/247,629 2015-10-28
US201662305875P 2016-03-09 2016-03-09
US62/305,875 2016-03-09
PCT/US2016/059192 WO2017075262A1 (en) 2015-10-28 2016-10-27 Use of beta-1,3-glucan for modulating immune function and treating intestinal inflammation

Publications (2)

Publication Number Publication Date
BR112018008401A2 true BR112018008401A2 (pt) 2018-10-23
BR112018008401B1 BR112018008401B1 (pt) 2023-08-01

Family

ID=

Also Published As

Publication number Publication date
US20180311271A1 (en) 2018-11-01
CN116440154A (zh) 2023-07-18
JP2023052414A (ja) 2023-04-11
US20210346423A1 (en) 2021-11-11
EP3368049A1 (en) 2018-09-05
US11744847B2 (en) 2023-09-05
US10912794B2 (en) 2021-02-09
US20240000825A1 (en) 2024-01-04
JP2018531977A (ja) 2018-11-01
AU2016344136A1 (en) 2018-05-10
EP3368049A4 (en) 2019-07-03
AU2016344136B2 (en) 2021-11-11
JP2021120383A (ja) 2021-08-19
WO2017075262A1 (en) 2017-05-04
CA3003330A1 (en) 2017-05-04
CN108430479A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
WO2016063263A3 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX2023000051A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
BR112017015059A2 (pt) inibidor de proteassoma e uso
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP4140487A8 (en) Combination therapy for treating cancer
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EP3368049A4 (en) USE OF BETA-1,3-GLUCAN FOR MODULATING THE IMMUNE FUNCTION AND TREATING A DARM IGNITION
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112012013720A2 (pt) uso cosmético de pelo menos um microorganismo probiótico, especialmente do gênero lactobacillus sp.e processo cosmético.
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
BR112018014445A2 (pt) composição que compreende toxina botulínica
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
BR112016025333A2 (pt) agente, produto e uso
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2016, OBSERVADAS AS CONDICOES LEGAIS